|Anne Auperin, Rodrigo Arriagada, Jean-Pierre Pignon, et al.|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Reviewers: Li Liu, MD
The brain is one of the most common sites for metastasis in small-cell lung cancer. Of patients who achieve a complete remission after chemotherapy +/- thoracic irradiation, in the absence of cranial irradiation, the probability of brain metastasis can be as high as 50% in 2-year survivors. Brain metastases are sometimes the only site of clinical relapse in complete responders and are often clinically devastating. Prophylactic cranial irradiation (PCI) significantly reduces the incidence of brain metastases. However, whether PCI improves overall survival remains debatable. This is a report of a meta-analysis on 7 randomized trials in an attempt to answer this question.
Only the trials that enrolled patients with histologically confirmed small-cell lung cancer in complete remission who were randomly assigned to receive PCI or no PCI, were included. Primary end point was overall survival, and analysis was on an intent to treat basis.
A total of 17 trials were identified. Among them 7 (including 1 unpublished trial) were eligible for analysis with a total of 987 patients. PCI dose was generally 24-40Gy in various fractionations. Twenty-five patients received 8Gy/1 fraction. The median follow up was 5.9 years (range from 3.5 to 18.5 years).
PCI not only significantly reduced the risk of brain metastasis among patients with small-cell lung cancer in complete remission, but also improved overall and disease-free survival. Partial or non-responders may not derive the equivalent benefit from PCI as compared with complete responders. The optimal dose and timing of PCI remain unclear at this point and should be studied in future trials.